Ignore "Ebola Stocks" Hype – This Medical Tech Leader Is Already Set Up to Treat the Next Major Outbreak

Keith Fitz-Gerald

Editor's Note: News just broke that the first U.S. case of Ebola has been confirmed in a patient in Dallas, Texas. The Sept. 30 announcement from the U.S. Centers for Disease Control and Prevention (CDC) sent "Ebola stocks" – the companies racing to get approval for treatment – up as much as 20% in after-hours trading. Keith Fitz-Gerald has been way out ahead of the story, tracking Ebola-related market developments for months for his paid members. Due to the importance of this breaking story, we're sharing his article and recommendations with all Money Morning readers.

As if ISIS, Gaza, and Ukraine weren't enough… now we've got to contend with an international outbreak of one of the deadliest viruses ever to threaten humanity – Ebola.

The virus kills 90% of the people who contract it. The World Health Organization (WHO) has declared the outbreak a worldwide public health emergency.

Yet we've seen this script before.

I don't mean to downplay Ebola. My point is: humanity has always struggled with pandemics, from the bubonic plague to bird flu. We always will. The "next Ebola" is already lurking somewhere out in the jungle. We can't know when it will attack or how to prepare for it. The only thing that's certain is we're going to have to deal with it, too.

From an investing standpoint, that means we don't need to spend a lot of mental energy worrying about what might be. Instead, we just need to continually seek out the best companies we can find based on a strict set of criteria, including expanding earnings, solid value, and globally recognized potential. Above all, we don't panic and we don't buy the hype. That's when you make the worst decisions for your wealth.

Indeed, the market is driving up Ebola vaccine stocks on nothing more than media hype – and then dropping them back down. Many of the experimental drug companies that might be working on an Ebola cure – Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR), Sarepta Therapeutics Inc. (Nasdaq: SRPT), BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) – are being knocked around Wall Street like so many Ping-Pong balls. TKMR popped 42% in one session in August, only to drop 22% a few days later. (If some guy calls you from a boiler room pitching an Ebola stock, hang up. He's probably long and trying to unload it.)

Trying to pin down which company will engineer a breakthrough treatment is almost impossible. For every success, there are thousands of failures, and for the smaller biotech firms focused on these highly specialized experimental drugs, even the smallest setback can kill a company.

That's what makes this opportunity so powerful…

Instead of trying to guess which company is going to come through with a cure for the latest deadly disease, I recommend you concentrate on companies making the best medical testing, diagnosis, and drug delivery systems. These products are going to be absolutely crucial moving forward – not only for the Ebola outbreak, but for the "next Ebola," the next public health concern, the next big demographic shift, right down to the next simple outpatient procedure or doctor visit.

And I've got great news for you. We already own just such a stock, and it's likely to power sharply higher in the next 12 months, adding to the 65.33% it's already returned for my Money Map Report subscribers.

It's the most powerful re-recommendation I've ever issued…

Join the conversation. Click here to jump to comments…

Keith Fitz-Gerald

About the Author

Browse Keith's articles | View Keith's research services

Keith Fitz-Gerald has been the Chief Investment Strategist for the Money Morning team since 2007. He's a seasoned market analyst with decades of experience, and a highly accurate track record. Keith regularly travels the world in search of investment opportunities others don't yet see or understand. In addition to heading The Money Map Report, Keith runs High Velocity Profits, which aims to get in, target gains, and get out clean, and he's also the founding editor of Straight Line Profits, a service devoted to revealing the "dark side" of Wall Street... In his weekly Total Wealth, Keith has broken down his 30-plus years of success into three parts: Trends, Risk Assessment, and Tactics – meaning the exact techniques for making money. Sign up is free at totalwealthresearch.com.

… Read full bio